Nektar Therapeutics (NKTR)

32.36
0.39 1.20
NASDAQ : Health Technology
Prev Close 31.97
Open 31.93
Day Low/High 31.82 / 32.68
52 Wk Low/High 29.22 / 69.76
Volume 626.53K
Avg Volume 1.52M
Exchange NASDAQ
Shares Outstanding 174.31M
Market Cap 5.59B
EPS 4.00
P/E Ratio 8.14
Div & Yield N.A. (N.A)
Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Monday as it changed hands at $8.54 compared with its previous 52-week low of $8.55. Nektar is currently trading at $8.55 with 520,531 shares changing hands as of 3:27 p.m. as compared to the average daily trading volume of 1.2 million.

10 Mid-Caps With Upside: Analysts

10 Mid-Caps With Upside: Analysts

Analysts expect these stocks to outperform their peers and broader markets.

Nektar Therapeutics Inc. Stock Downgraded By TheStreet Ratings (NKTR)

Nektar Therapeutics Inc. Stock Downgraded By TheStreet Ratings (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) has been downgraded by TheStreet Ratings from from a hold to sell.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Thursday as it changed hands at $9.59 compared with its previous 52-week low of $9.75. Nektar is currently trading at $9.74 with 226,122 shares changing hands as of 11:02 a.m. as compared to the average daily trading volume of 1.1 million.

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Stock Hits New 52-Week Low (NKTR)

Nektar Therapeutics (Nasdaq:NKTR) hit a new 52-week low Wednesday as it changed hands at $10.34 compared with its previous 52-week low of $10.38. Nektar is currently trading at $10.34 with 274,464 shares changing hands as of 10:32 a.m. as compared to the average daily trading volume of 1.1 million.

J.P. Morgan Healthcare Confab: Live Blog

J.P. Morgan Healthcare Confab: Live Blog

TheStreet's biotech columnist Adam Feuerstein is providing live biotech coverage of the J.P. Morgan Healthcare Conference in San Francisco.

Nektar CEO Discusses Q3 2010 Results - Earnings Call Transcript

Nektar CEO Discusses Q3 2010 Results - Earnings Call Transcript

Nektar CEO Discusses Q3 2010 Results - Earnings Call Transcript

Nektar Therapeutics Q2 2010 Earnings Call Transcript

Nektar Therapeutics Q2 2010 Earnings Call Transcript

ASCO Live Blog: Monday

Today is the last day of the American Society of Clinical Oncology annual meeting. Here are the highlights, live.

ASCO Live Blog: Sunday

Here are the highlights from the second full day of clinical data presentations at ASCO 2010.

13 ASCO Stocks Presenting New Clinical Data

Here's the updated list of biotech and drug stocks that will be presenting new clinical data at this year's American Society of Clinical Oncology meeting.

Nektar Therapeutics Q1 2010 Earnings Call Transcript

Nektar Therapeutics Q1 2010 Earnings Call Transcript

13 Biotech Stocks Presenting New Clinical Data

Here's a list of biotech and drug stocks that will be presenting new clinical data at this year's American Society of Clinical Oncology meeting.

Moving On Up

Even though sellers knocked prices down in the afternoon, it will take more than that to stop the current rally.

Turnaround Still Possible

Despite getting sucker-punched, buyers haven't yet been given enough time or opportunity to lose faith and give up.

Movers Roundup: Rite Aid, Nektar Therapeutics

Movers Roundup: Rite Aid, Nektar Therapeutics

Movers roundup: Rite Aid downgraded, Nektar drug candidate effective in early study

Nektar Climbs On Trial Data And Partnership

Nektar Climbs On Trial Data And Partnership

Nektar Therapeutics sets two-year high as ovarian cancer drug data follows AstraZeneca pact

Health Care Funds Get Obama Bounce

Health Care Funds Get Obama Bounce

The average health care fund rose 1.5% in the past week as investors mulled Obama's health care plan.

Nektar Shares Rise On Morgan Joseph Analyst View

Nektar Shares Rise On Morgan Joseph Analyst View

Nektar Therapeutics shares rise as Morgan Joseph analyst maintains positive outlook

Nektar Shares Rise As Partner Gets FDA Approval

Nektar Shares Rise As Partner Gets FDA Approval

Nektar Therapeutics shares rise as partner receives FDA approval on potential blockbuster

RA Patients Choose Pain Over Poverty: Survey

The weakened economy is causing rheumatoid arthritis patients to put off or delay treatment with expensive injectable drugs and pressuring the leading market players.

Health Winners & Losers: Omrix

Seattle Genetics rises, but Alnylam falls.

Novartis to Buy Nektar's Pulmonary Business

Novartis to Buy Nektar's Pulmonary Business

The Swiss drug maker will acquire the assets for $115 million in cash.

Jim Cramer's Best Blogs

Jim Cramer's Best Blogs

Catch up on his thinking on the hottest topics of the past week.

Feuerstein's Biotech-Stock Mailbag

Feuerstein's Biotech-Stock Mailbag

The latest M&A and what it means more broadly; tapping Russia for drug approvals; the next potential insulin play and more.

Thursday's Health Winners & Losers

Thursday's Health Winners & Losers

Millennium Pharma surges on buyout news.

Wednesday's Winners & Losers: MannKind

Wednesday's Winners & Losers: MannKind

Shares plummet on fears the company's main drug will fail.

Wednesday's Health Winners & Losers

Wednesday's Health Winners & Losers

Nektar and MannKind tumble on inhaled insulin drug data.

Inhaled Insulin Dependence Leaves MannKind Gasping

Shares of the biotech free fall on fears its lead drug candidate may never make it to market.

Nektar Gives Up on Inhaled Insulin

Latest study data serve as the death knell for the Exubera program, and also send shares of competitor Mannkind lower.

TheStreet Quant Rating: C (Hold)